Global NasalDrug Delivery Systems Market, by Dosage Form (Nasal Spray, Nasal Drops,Nasal Gels, Nasal Powders, and Others), by Container Type (Non-pressurized Containersand Pressurized Containers), by System Type (Multi-dose, Bi-dose, and UnitDose), by Therapeutics Application (Allergic and Non-allergic Rhinitis, NasalCongestion, Vaccination, and Others), by Distribution Channel (HospitalsPharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa) isestimated to be valued at US$ 48.1 billion in 2018, and is projected to exhibita CAGR of 6.3% over the forecast period (2018 – 2026).
Novel drug delivery systems areone of the fastest growing segment in the pharmaceutical industry. Nasal is atransmucosal drug delivery system, used to administer drug through nasalcavity. Numerous studies are conducted to study the systemic bioavailability ofdrug and on nasal administration of vaccine, peptide and hormonal therapy, andother drugs which are usually delivered by parenteral route.
Growth in nasal drug deliverysystem market is attributed to high advantages of nasal administration andincreasing innovative nasal drug delivery systems. Moreover, expandingtherapeutic application is expected to drive growth of the nasal drug deliverysystems market. For instance, number of pharmaceutical and biopharmaceuticalcompanies are adopting nasal drug delivery system for the treatment of acutemigraine, pain management, Alzheimer disease etc.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1944
For instance, in 2016, LannettCompany, Inc. received Abbreviated New Drug Application (ANDA) approval fromthe U.S. FDA for its Sumatriptan Nasal Spray intended for the treatment ofmigraine. Moreover, in June 2018, Impax Specialty Pharma, Inc., a specialtypharmaceutical company, received US FDA approval for Zomig Nasal Spray to treatacute migraine in patients aged 12 years and above.
Furthermore, in 2017, FDAapproved OptiNose U.S. Inc.’s Xhance, which is a novel combination of drug anddevice to deliver fluticasone propionate to treat nasal polyps. Such productlaunches with diverse therapeutic application are augmenting the nasal drugdelivery systems market growth.
Browse Market Data 40 Tables and38 Figures spread through 180 Pages and in-depth TOC on "Nasal DrugDelivery Systems Market, by Dosage Form (Nasal Spray, Nasal Drops, Nasal Gels,Nasal Powders, and Others), by Container Type (Non-pressurized Containers andPressurized Containers), by System Type (Multi Dose, Bi Dose, and Unit Dose),by Therapeutics Application (Allergic and Non-allergic Rhinitis, NasalCongestion, Vaccination, and Others), by End User (Hospitals and Home CareSettings) and by Region - Global Forecast to 2026”
Market players in nasal drugdelivery systems are focusing on inorganic strategies, in turn consolidatingthe market. For instance, in 2014, Endo International plc, acquired Natesto,the first and only testosterone nasal gel till that date, from Trimel BioPharmaSRL, used for the treatment of hypogonadism via replacement therapy.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/nasal-drug-delivery-systems-market-1944
Furthermore, in 2015, Eli Lillyand Company acquired Locemia's intranasal glucagon, which was in phase IIIclinical testing for the treatment of hypoglycemia. Such product acquisition isexpected to strengthen the company’s product portfolio, in turn strengtheningthe market share of the acquirer.
Key takeaways of the Nasal DrugDelivery Systems Market:
The global nasal drug deliverysystems market is expected to expand at a CAGR of 6.3% during the forecastperiod (2018 – 2026), owing to increasing approvals for nasal drug deliverysystems
Nasal spray segment is expectedto be dominant, owing to large number of products offered in this segment andincreasing research to launch new products in this segment
Some of the major playersinvolved in global nasal drug delivery systems market include Merck & Co.,GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc.,Baxter International, Inc., Valeant Pharmaceuticals International, Inc.,Becton, Dickinson and Company, and Novartis AG
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1944
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
